/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE
SERVICES OR FOR DISSEMINATION IN THE
UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION
MAY CONSTITUTE A VIOLATION OF U.S. SECURITIES LAWS./
TORONTO, Aug. 8, 2017 /CNW/ - Further to its press release
dated August 2, 2017, Scythian
Biosciences Corp. (the "Company" or "Scythian",
formerly Kitrinor Metals Inc., (TSXV: SCYB) is pleased to announce
that the Company has received approval from the Toronto Venture
Exchange Inc. (the "TSXV") to list its common shares on the
TSXV as a research and development in the physical, engineering and
life sciences company. The common shares of the Company commenced
trading on the TSXV at the opening of market today, Tuesday, August 8, 2017, under the trading symbol
"SCYB".
Scythian's CEO and Chairman commented, "We are pleased to have
completed this major milestone. The TSXV listing represents greater
accessibility and liquidity to a broader group of investors and
increased market recognition. We will continue to work with the
University of Miami's research team to
develop a drug regime that can treat concussions and traumatic
brain injury."
About Scythian Biosciences Corp.
Scythian is a research and development company committed to
finding a solution for the prevention and treatment of concussions
and traumatic brain injury with its proprietary Cannabinoid
combination.
Scythian's mission is to be the first accepted drug regimen for
concussive treatment. Scythian has recently formed a collaboration
with the University of Miami and its
world renowned neuroscientific team to conduct pre-clinical and
clinical trials of its drug regimen. The University of Miami believes that Scythian's
scientific approach shows significant promise and differs from
previous approaches to treat this growing problem. The
collaboration with the University of
Miami allows access to their extensive knowledge base in the
fields of traumatic brain injury and concussions and allows for
Scythian's clinical studies to be undertaken at their world-class
facilities.
Gillian A. Hotz, PhD, is leading
Scythian's program at the University of Miami. Dr. Hotz is a
nationally recognized behavioral neuroscientist and expert in
neurotrauma, concussion management, and neurorehabilitation.
She has extensive experience in neurocognitive testing. Dr.
Hotz has been the co-director of University of
Miami Miller School of Medicine's Concussion Program since
1995.
Scythian is also endorsed by Pro Football Legends and the World
Boxing Association on its mission.
Cautionary Statements
This press release may contain certain forward-looking
information and statements ("forward-looking
information") within the meaning of applicable Canadian
securities legislation, that are not based on historical fact,
including without limitation statements containing the words
"believes", "anticipates", "plans", "intends", "will", "should",
"expects", "continue", "estimate", "forecasts" and other similar
expressions. Readers are cautioned to not place undue
reliance on forward-looking information. Actual results and
developments may differ materially from those contemplated by these
statements. The Company undertakes no obligation to comment
on analyses, expectations or statements made by third-parties
in respect of the Company, its securities, or financial or
operating results (as applicable). Although the Company
believes that the expectations reflected in forward-looking
information in this press release are reasonable, such
forward-looking information has been based on expectations, factors
and assumptions concerning future events which may prove to be
inaccurate and are subject to numerous risks and uncertainties,
certain of which are beyond the Company's control, including the
risk factors discussed in the Filing Statement which are
incorporated herein by reference and are available through SEDAR
at www.sedar.com. The forward-looking information
contained in this press release are expressly qualified by this
cautionary statement and are made as of the date hereof. The
Company disclaims any intention and has no obligation or
responsibility, except as required by law, to update or revise any
forward-looking information, whether as a result of new
information, future events or otherwise.
SOURCE Scythian Biosciences Corp.
